Department of Medicinal Chemistry and Pharmacognosy, University of Illinois College of Pharmacy, 833 S. Wood Street, Chicago, IL 60612-7231, USA.
J Pharmacol Exp Ther. 2011 Nov;339(2):716-25. doi: 10.1124/jpet.111.185405. Epub 2011 Aug 24.
Prostaglandins (PGs) are a family of cellular messengers exerting diverse homeostatic and pathophysiologic effects. Recently, several studies reported significant increases of PGI(2) and PGF(2α) after the inhibition of microsomal PGE synthase-1 (mPGES-1) expression, which indicated that PGH(2) metabolism might be redistributed when the PGE(2) pathway is blocked. To address the determinants that govern the relative amounts of PGs, we developed an in vitro cell-free method, based on liquid chromatography-tandem mass spectrometry, to measure the exact amounts of these PGs formed in response to the addition of recombinant isomerases and their selective inhibitors. Our in vitro cell-free assay results were confirmed in cells using bone marrow-derived macrophage. Initially, we determined the in vitro stability of PGH(2) and noted that there was spontaneous nonenzymatic conversion to PGD(2) and PGE(2). mPGES-1 markedly increased the conversion to PGE(2) and decreased conversion to PGD(2). Reciprocally, the addition of hematopoietic or lipocalin PGD synthase resulted in a relative increase of PGD(2) and decrease of PGE(2). A detailed titration study showed that the ratio of PGE(2)/PGD(2) was closely correlated with the ratio of PGE synthase/PGD synthase. Our redistribution results also provide the foundation for understanding how PGH(2) metabolism is redistributed by the presence of distal isomerases or by blocking the major metabolic outlet, which could determine the relative benefits and risks resulting from interdiction in nonrated-limiting components of PG synthesis pathways.
前列腺素(PGs)是一类细胞信使分子,具有多种体内平衡和病理生理作用。最近,几项研究报告称,在抑制微粒体前列腺素 E 合酶-1(mPGES-1)表达后,PGI(2)和 PGF(2α)显著增加,这表明当 PGE(2)途径被阻断时,PGH(2)代谢可能会重新分布。为了确定决定 PG 相对含量的因素,我们开发了一种基于液相色谱-串联质谱的体外无细胞方法,以测量在添加重组异构酶及其选择性抑制剂时形成的这些 PG 的准确含量。我们的体外无细胞测定结果在骨髓来源的巨噬细胞中得到了验证。最初,我们确定了 PGH(2)的体外稳定性,并注意到其自发地发生非酶转化为 PGD(2)和 PGE(2)。mPGES-1 显著增加了向 PGE(2)的转化,减少了向 PGD(2)的转化。相反,添加造血或脂联素 PGD 合酶导致 PGD(2)的相对增加和 PGE(2)的减少。详细的滴定研究表明,PGE(2)/PGD(2)的比值与 PGE 合酶/PGD 合酶的比值密切相关。我们的重分布结果也为理解 PGH(2)代谢如何通过存在远端异构酶或通过阻断主要代谢出口而重新分布提供了基础,这可能决定了阻断 PG 合成途径中非限速成分所带来的相对益处和风险。